Quest Diagnostics Incorporated (DGX)
|Net Income (ttm)||2.25B|
|Ex-Dividend Date||Oct 4, 2021|
|Day's Range||143.98 - 146.57|
|52-Week Range||112.33 - 159.87|
|Price Target||160.13 (+9.3%)|
|Est. Earnings Date||n/a|
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent ... [Read more...]
In 2020, DGX's revenue was $9.44 billion, an increase of 22.15% compared to the previous year's $7.73 billion. Earnings were $1.43 billion, an increase of 66.78%.Financial Statements
According to 18 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is 160.13, which is an increase of 9.31% from the latest price.
Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 33.78% and 12.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Incorporated (NYSE: DGX) has posted a better-than-expected Q3 adjusted EPS of $3.96, down 7.9% Y/Y, beating the consensus estimate of $2.87. Sales came in at $2.77 billion, a marginal ...
U.S. laboratory Quest Diagnostics Inc on Thursday reported a 11% fall in third-quarter profit as the spread of the highly contagious Delta variant weighed on demand for its non-coronavirus businesses.
SECAUCUS, N.J., Oct. 21, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third...
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Quest Diagnostics to Provide K-12 School COVID-19 Testing in Collaboration with Ginkgo Bioworks to Support Safer Clas...
SECAUCUS, N.J. and IRVING, Texas and BOSTON, Oct. 20, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced it has formed a...
Quest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Company's Ve...
SECAUCUS, N.J., Oct. 18, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it will provide clinical laboratory tes...
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.
Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.
Quest Diagnostics CEO on the future of Covid testing
Meg Tirrell joins The Exchange with Quest Diagnostics CEO Steve Rusckowski to discuss the future of Covid testing. As the flu and cold seasons return, Rusckowski says, he expects more people will turn u...
SECAUCUS, N.J., Oct. 12, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, has completed its integration of Northeast regi...
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Hibbett (HIBB), O'Reilly Automotive (ORLY), The Interpublic Group of ...
Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.
Here are five out of the 14 stocks, TSCDY, REGN, DGX, EQNR and MAKSY that qualified the screening.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
The heavy selling pressure might have exhausted for Quest Diagnostics (DGX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street anal...
Quest Diagnostics and the Boston Athletic Association Team Up to Provide Onsite COVID-19 Diagnostic Testing for the 1...
BOSTON and SECAUCUS, N.J., Oct. 5, 2021 /PRNewswire/ -- The Boston Athletic Association (B.A.A.
SECAUCUS, N.J., Sept. 29, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 20...
Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).
Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.
Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.
On the back of steady demand for COVID-19 testing, Quest Diagnostics bumped up its guidance for this year.